Noela Carrera-Guermeur1, Rosa M Martín-Crespo2, Hilda J Ramírez3, Ángel Pantoja4, Rafael Luque-Mialdea5. 1. Department of Pediatric Surgery, Complejo Hospitalario de Toledo, Avenida de Barber, No 30, 45004, Toledo, Spain. noelacarrera@hotmail.com. 2. Department of Pediatric Surgery, Complejo Hospitalario de Toledo, Avenida de Barber, No 30, 45004, Toledo, Spain. rmartincrespo@movistar.es. 3. Department of Pediatric Surgery, Complejo Hospitalario de Toledo, Avenida de Barber, No 30, 45004, Toledo, Spain. hilda_317@hotmail.com. 4. Division of Neonatology, Department of Pediatrics, Complejo Hospitalario de Toledo, Avenida de Barber, No 30, 45004, Toledo, Spain. angelp@sescam.jccm.es. 5. Department of Pediatric Surgery, Complejo Hospitalario de Toledo, Avenida de Barber, No 30, 45004, Toledo, Spain. rluquemialdea@telefonica.net.
Abstract
UNLABELLED: Enterocutaneous fistula and its conservative management still pose a challenge for the surgeon. The use of octreotide and somatostatin in neonates and children as adjunctive therapy in the conservative management of this condition, leads to major controversy regarding its efficacy. Therefore, we conducted an extensive literature review of published articles regarding the use of somatostatin and its analogues in the treatment of enterocutaneous fistula in neonates and children. Our review is then presented together with a case vignette and discusses the different practical aspects of the treatment with these drugs. CONCLUSION: The major diversity in treatment regimens among published studies makes outcomes difficult to compare. However, given the results of the different cases reported in the literature and of our own experience, we suggest a possible beneficial effect of octreotide and somatostatin on closure of enterocutaneous fistula in these patients.
UNLABELLED: Enterocutaneous fistula and its conservative management still pose a challenge for the surgeon. The use of octreotide and somatostatin in neonates and children as adjunctive therapy in the conservative management of this condition, leads to major controversy regarding its efficacy. Therefore, we conducted an extensive literature review of published articles regarding the use of somatostatin and its analogues in the treatment of enterocutaneous fistula in neonates and children. Our review is then presented together with a case vignette and discusses the different practical aspects of the treatment with these drugs. CONCLUSION: The major diversity in treatment regimens among published studies makes outcomes difficult to compare. However, given the results of the different cases reported in the literature and of our own experience, we suggest a possible beneficial effect of octreotide and somatostatin on closure of enterocutaneous fistula in these patients.
Authors: Goher Rahbour; Muhammed R Siddiqui; Mohammad Rehan Ullah; Simon M Gabe; Janindra Warusavitarne; Carolynne J Vaizey Journal: Ann Surg Date: 2012-12 Impact factor: 12.969
Authors: R Karabulut; C Karakuş; I Hirfanoğlu; O Turan; Z Türkyilmaz; K Sönmez; E E Onal; Y Atalay; A C Başaklar Journal: Eur J Pediatr Surg Date: 2008-02 Impact factor: 2.191